To the full analysis
PTC Therapeutics stock: growth
PTCTPTC Therapeutics reported $1.73B in revenue for fiscal 2025, up 114.5% on the prior year, up 35.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
22.7%
per year from 2011 to 2025, per share 8.5%
Earnings (Annual rate)
24.7%
per year from 2011 to 2025, per share 83.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 35.4% | 47.0% | 22.7% |
| Revenue per share | 30.4% | 34.9% | 8.5% |
| Earnings | no data | no data | 24.7% |
| Earnings per share | no data | no data | 83.1% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $98.96M | $30.9M | −$20.93M |
| 2012 | $28.78M | −$26.24M | −$48.12M |
| 2013 | $31.33M | −$51.57M | −$47.77M |
| 2014 | $22.96M | −$93.75M | −$61.94M |
| 2015 | $36.77M | −$170.45M | −$127.06M |
| 2016 | $82.71M | −$142.11M | −$105.34M |
| 2017 | $194.39M | −$79M | −$13.16M |
| 2018 | $264.73M | −$128.08M | −$43.17M |
| 2019 | $306.98M | −$251.58M | −$144.08M |
| 2020 | $380.77M | −$438.16M | −$250.05M |
| 2021 | $538.59M | −$523.9M | −$336.66M |
| 2022 | $698.8M | −$559.02M | −$509.11M |
| 2023 | $937.82M | −$626.6M | −$279.04M |
| 2024 | $806.78M | −$363.3M | −$181.94M |
| 2025 | $1.73B | $682.64M | $411.18M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.